
Tirzepatide beat testosterone therapy for raising testosterone in obese men (pilot, n=83)
Louis argues that low testosterone in middle-aged men is mainly driven by visceral fat and should be treated by fat loss rather than TRT. The shared pilot study in 83 men with obesity found tirzepatide plus lifestyle gave the greatest weight and fat loss and raised testosterone, LH and FSH more than lifestyle alone or TRT.
